C igarette smoking is a major reversible risk factor for cardiovascular disease (CVD).
improve with smoking cessation. 4 Accordingly, it is important, particularly from a regulation science perspective, to determine which measures of subclinical vascular disease are most reflective of the negative impact of smoking to allow for timely evaluation of the impact of tobacco products, old and new, 5 on cardiovascular health. Similarly, determining whether any of the associations between smoking and these subclinical measures demonstrate reversibility with increased time since smoking cessation could suggest options to monitor vascular recovery post-tobacco cessation.
The Multi-Ethnic Study of Atherosclerosis (MESA) is an extensively characterized, diverse, contemporary cohort, affording the opportunity to conduct a rigorous cross-sectional examination of the impact of smoking on 3 domains of preclinical CVD: inflammation, vascular dynamics and function, and subclinical-atherosclerosis. Specifically, we sought to determine the influence of smoking on these 3 CVD domains by testing the following: (1) the strength of association between smoking status and each domain; (2) whether these associations demonstrated a dose-response relationship with cumulative smoking exposure by quartiles of pack-years; and (3) whether these associations attenuate with time since cessation in former smokers.
For the purposes of this analysis, inflammation was assessed using high-sensitivity C-reactive protein (hsCRP), fibrinogen, and interleukin-6 (IL-6). Vascular dynamics (distensibility) was measured by both aortic MRI and carotid ultrasound, and vascular endothelial function was estimated by brachial artery flow-mediated dilation (FMD). Finally, subclinical atherosclerosis was measured at 3 anatomically distinct vascular sites using carotid intima-media thickness (CIMT), coronary artery calcification (CAC), and ankle-brachial index (ABI). Thus, this study represents one of the most comprehensive analyses of the impact of smoking on subclinical vascular disease to date and is well positioned to inform regulatory policy around tobacco products.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Baseline Demographics
Results of the cotinine reclassification are displayed in Table  I in the online-only Data Supplement. After reclassification, current smokers comprised 971 (14%), former smokers 2607 (38%), and never smokers 3218 (47%) of MESA participants.
Current smokers were younger than never smokers and were more likely to be male. Other baseline differences are shown in Table 1 . The highest prevalence of current smoking was noted in blacks and the lowest in Chinese Americans. Despite their younger age, mean (±SD) pack-years of smoking was higher in current smokers (29.5 [±24.6] ), compared with former smokers (21 [±25.2], P<0.001). Among former smokers, the mean (±SD) time elapsed between cessation and study enrollment was 22 (±13) years.
Smoking and Inflammation
Crude hsCRP levels was significantly higher in current smokers than in never smokers (median 2.5 mg/L versus 1.8 mg/L, P<0.001; Table 1 ). Median hsCRP in former smokers was 1.9 mg/L. There were also linear trends of higher crude IL-6 levels in current and former smokers, compared with never smokers (Table 1) . However, no significant linear trend was seen between crude Fibrinogen levels and smoking status categories (P=0.25).
After full adjustment, current smokers and former smokers continued to demonstrate elevated hsCRP and IL-6 compared with never smokers, with stronger relative associations for current smokers (Table 2 ). For instance, compared with never smokers, the odds of hsCRP ≥2 mg/L was almost 2-fold elevated for current smokers (odds ratio [OR] of 1.8 [95% confidence interval, 1.5-2.1]). This contrasts with an OR of 1.2 (1.1-1.4) for former smokers. Adjusted fibrinogen levels were higher in current smokers but lower in former smokers, compared with never smokers. Further adjustment for alcohol intake, recent fever, and anti-inflammatory medications (aspirin, NSAIDS [non-steroidal anti-inflammatory drugs], or steroids) did not alter the association between smoking and these inflammatory markers (Table II in the online-only Data Supplement) .
Similarly, adjusted hsCRP and IL-6 estimates increased in a monotonic fashion among higher quartiles of pack-year history (Table 3) . These relative increases were more pronounced in current smokers than in former smokers, and all met statistical significance in the fourth quartile of pack-years compared with the first quartile. For example, the OR of hsCRP ≥2 mg/L was 1.7 (1.3-2.2) for former smokers in the highest quartile of packyears and 2.6 (1.7-4.1) for current smokers in the highest quartile of pack-years (both relative to the first quartile in each smoking category). Only current smokers in the highest quartile of packyears had relative increases in adjusted fibrinogen (Table 3) .
The associations between smoking status and these 3 inflammatory biomarkers were qualitatively similar in males and females, with no evidence for interaction (with the single exception of higher fibrinogen levels in male smokers [P-interaction=0.01]; Table III in the online-only Data  Supplement) . When stratified by ethnicity, the association between smoking status and hsCRP persisted in Whites and blacks. In contrast, this association was less significant in Chinese-American and Hispanics (Table IV in the online-only Data Supplement). However, there was no evidence that ethnicity modified the effect of smoking status on hsCRP levels overall (interaction P=0.89).
Furthermore, for every 5-year period that had passed between smoking cessation and the baseline MESA ABI indicates ankle-brachial index; CAC, coronary artery calcium; CIMT, carotid intima-media thickness; CVD, cardiovascular disease; FMD, flow-mediated dilation; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol; and NSAID, non-steroidal anti-inflammatory drug.
*Values are mean (±SD), median (25th-75th), or proportions (%). †In addition to standard P values, for each crude outcome we also calculated P values for trend calculated using a nonparametric test across ordered groups. All P values for linear trend are <0.001, except fibrinogen (P trend=0.25), aortic distensibility (P trend=0.20), and FMD (P trend=0.04).
‡All values are for entire study sample except for carotid distensibility (n=6516 subjects), aortic distensibility (n=3530 subjects), and FMD (n=3027 subjects). CAC percentiles were calculated in those with CAC>0 at baseline (n=3392) and are based on age, race, and sex. assessment, former smokers tended to have lower hsCRP levels (eg, OR of 0.91 [0.88-0.95] for hsCRP ≥2 mg/dL, Table 2 , Figure 1 ). Notably, there was a negative correlation between smoking cessation interval and pack-years exposure in former smokers (Spearman correlation coefficient of −0.47, P<0.001). Nonetheless, the smoking cessation interval OR for hsCRP ≥2 mg/dL was essentially unchanged in a sensitivity analysis performed with pack-years further added to the fully adjusted Table 2 Table V in the online-only Data Supplement). Therefore, to illustrate further, former smokers with 15 years of cessation before the baseline MESA visit had an 8% to 9% lower odds of having hsCRP>2 mg/dL at baseline, compared with former smokers who were abstinent for 10 years. Lower relative IL-6 levels were also present per 5-year cessation interval, a finding that was also robust to further adjustment for pack-years in the model (Table 2; Table V in the onlineonly Data Supplement). However, years since cessation was not associated with lower fibrinogen.
Smoking and Vascular Dynamics and Function
In the representative MESA subsamples who underwent aortic MRI and FMD testing, the proportion of current smokers was identical to the overall analysis sample (Table VI in the online-only Data Supplement). In crude (Table 1) and  adjusted (Table 2) analyses, carotid distensibility was higher in current smokers compared with never and former smokers. In contrast, aortic distensibility was lower in former and current smokers compared with never smokers. After adjustment, there were no significant differences in brachial FMD among any of the smoking status categories. Stratification by pack-years cumulative smoking exposure did not influence these null associations (Table 3) . Furthermore, neither age nor sex modified the effect of smoking on any of these 3 outcomes (P-interaction for all >0.05). In addition, time since cessation in former smokers was not associated with differences in vascular dynamics or function within the MESA cohort (Table 2 ).
Smoking and Subclinical Atherosclerosis
Both smoking groups had higher crude and adjusted internal CIMT compared with never smokers. We found similar relationships for CAC (Tables 1 and 2 ). For example, current smokers were more likely than never smokers to have a CAC score >75th percentile for age, sex, and race (adjusted OR, 1.38 [1.08-1.77]); however, the association for former smokers was weaker (adjusted OR, 1.18 [0.99-1.41], Table 2 ). Although both former smokers and current smokers demonstrated higher odds of CAC>0 compared with never smokers, the association was again stronger in current smokers. Similar crude and adjusted associations were also demonstrated for reduced ABI. Further adjustment for alcohol intake, recent fever, or anti-inflammatory medications did not appreciably change any of these results (Table II in the onlineonly Data Supplement) . When stratified by pack-year cumulative exposure, only former smokers in the highest quartile of pack-years had increased CIMT (Table 3) . There was also a graded increase in odds for CAC>0 in former smokers with higher cumulative smoking exposure (OR of 1.6 for second quartile of packyears, 1.7 for third quartile, and 2.0 for the fourth quartile, all compared with first quartile). A similar association was also seen for reduced ABI (Table 3) . In contrast to former smokers, associations between pack-year quartiles and subclinical atherosclerosis were mostly null in current smokers.
The above associations between smoking status and the presence of CAC were generally similar when stratified by ethnicity. As with hsCRP, associations appeared weaker for Chinese Americans (Table IV in the online-only Data Supplement). However, once again, there was no evidence for effect modification by ethnicity (interaction P=0.92 for OR CAC>0 by smoking status). Similarly, there was no consistent evidence that sex modified the effect of smoking on these subclinical atherosclerosis measures (Table III in The time interval between the onset of smoking cessation and subsequent testing at the baseline MESA visit was also associated with reduced burden of subclinical-atherosclerosis in former smokers, both by year since cessation and rescaled to intervals of 5 years since cessation (Table 2; Figure 1 
Atherosclerosis in Smokers With and Without Inflammation (Testing Effect Modification)
Although smoking status was associated with CAC overall, Figure 2 shows that smokers with hsCRP levels ≥2 mg/L were more likely to have relatively higher adjusted CAC than smokers without inflammation. This trend persisted after further adjustment for pack-years (Table VII in the online-only Data Supplement). Of note, both former smokers and current smokers had an increased odds for CAC>0 (compared with never smokers), whether or not hsCRP was ≥2 mg/L. However, the point estimates increased monotonically in each of the 4 groups, ranging from former smokers without inflammation to current smokers with inflammation ( Figure 2 ). In contrast, only current smokers with active inflammation were at risk for CAC levels greater than the 75th percentile for age, sex, and race (OR 1.6 [1.2-2.3]). Inflammation appeared to modify the effect of smoking on the likelihood of severe CAC>75th percentile (interaction P value=0.01, Figure 2 ), but not for milder disease (interaction P=0.20 for CAC>0). Furthermore, we also found evidence that elevated inflammatory markers also adversely modify the effect of smoking on both CIMT severity (interaction P=0.02) and on ABI<1 (interaction P=0.004; Table VIII in the online-only Data Supplement).
Discussion
In this multi-ethnic cohort free of known CVD, both former and current smoking status were independently associated with markers of inflammation and subclinical atherosclerosis. These cross-sectional associations were stronger for current smokers than for former smokers. In addition, there was evidence of a graded increase in association between higher levels of cumulative tobacco exposure and markers of inflammation. These findings were statistically similar among sex and ethnicity categories. Smokers with elevated inflammatory markers were also more likely to have an increased burden of subclinical atherosclerosis and, importantly, we extend prior knowledge by demonstrating significant interaction for inflammation (specifically elevated hsCRP) on the association between smoking status and measures of subclinical atherosclerosis at all 3 anatomically distinct sites. In the context of established data supporting a causal role for smoking in the pathogenesis of atherosclerosis, this interaction is strongly suggestive of effect modification. However, none of the smoking parameters evaluated were consistently associated with adverse markers of vascular dynamics and function.
This analysis is one of the first to comprehensively focus on the interplay of smoking parameters and 3 diverse domains of vascular disease: inflammation, vascular dynamics and function, and subclinical atherosclerosis. In addition, although prior cohort studies have been ethnically homogenous, our data derive from a rigorously conducted, well-characterized, community-based, multi-ethnic cohort. Similarly, by using available urinary cotinine where possible (see methods in the online-only Data Supplement for details), we minimized misclassification (and reporting bias) of the smoking exposure variables. We think that our findings have important implications for tobacco regulatory science by shedding light on those measures of subclinical CVD that are most reflective of the effect of smoking to facilitate evidence based, efficient, and timely evaluation of new tobacco products on cardiovascular health.
In addition, our results also provide new insights into the impact of smoking cessation on CVD. Specifically, the association between smoking and inflammation, and to a lesser extent smoking and atherosclerosis, both attenuate with years since cessation in former smokers, providing supporting evidence for the beneficial cardiovascular effects of smoking cessation. These results also suggest potential opportunities for monitoring the response of smoking cessation on vascular health.
Smoking and Inflammation
The emerging risk factors collaboration reported that hsCRP levels were 37% (95% confidence interval, 31%-44%) higher in current smokers compared with never smokers. 6 Our results confirm these findings by demonstrating that both current and former smoking status are independently associated with Figure 2 . Association of smoking with coronary calcium, based on inflammatory status (see also Table VII in the online-only Data Supplement). *All odds ratios are compared with never smokers with high-sensitivity C-reactive protein (hsCRP) <2 mg/L. Error bars indicate 95% confidence intervals. Logistic model is adjusted for age, sex, race, Multi-Ethnic Study of Atherosclerosis (MESA) site, body mass index, hypertension status, diabetes mellitus status, heart rate, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, treatment for dyslipidemia, family history of myocardial infarction, and level of education. †Interaction of hsCRP on smoking status and CAC>75th percentile; P=0.01. ‡Interaction of hsCRP on smoking status and CAC>0; P=0.20. CAC>75th percentile indicates artery calcium greater than the 75th percentile for age, sex, and race; CAC>0 AU, coronary artery calcium greater than zero Agatston units; CS, current smokers; and FS, former smokers. elevated hsCRP in this multiethnic sample. Moreover, we determined that these independent associations were incrementally stronger in the highest quartile of pack-years cumulative smoke exposure. In such, our data confirm prior studies suggesting an association between cumulative smoke exposure and hsCRP. 7 Furthermore, we extend prior reports by studying more proximal inflammatory markers which are thought to activate earlier in the inflammatory cascade than hsCRP. Fibrinogen is a proinflammatory and prothrombotic marker and has been correlated with increased CVD risk.
8 Soluble IL-6 has also been associated with increased CVD. [9] [10] [11] We add to prior data by demonstrating an association between both smoking status and cumulative smoking exposure with IL-6. Results for fibrinogen were less consistent.
Finally, we found that the associations with hsCRP and IL-6 are weaker for former smokers compared with current smokers, and that they further attenuate with increased time since quitting in former smokers. Reichert et al 12 previously reported that smoking cessation led to immediate reductions in proximate markers of inflammation. However, previous population studies have suggested that more distal markers (eg, hsCRP) can take as many as 5 years to improve. 13 An analysis from NHANES (National Health and Nutrition Examination Survey) also found an improvement in hsCRP levels 5 years after smoking cessation.
14 However, in MESA, our results suggest that there may be small but statistically significant reductions in both hsCRP and IL-6 after just 1 year relative difference in smoking cessation (with cessation time modeled as a continuous variable). Although this result is based on a statistical model of cross-sectional data, and will therefore require replication, our results suggest that hsCRP may be useful in monitoring the acute effects of smoking cessation on vascular health.
Smoking and Vascular Dynamics and Function
The lack of a consistent association between smoking and either vascular distensibility (by both aortic MRI and carotid ultrasound) or endothelial function (brachial FMD) was an unexpected finding. Previous studies have suggested that smoking is associated with FMD in a dose-dependent manner. 15 Prior studies have also reported improved endothelial function by FMD in smokers who successfully maintain abstinence 1 year after cessation. 4 In addition, smoking has been previously associated with measures of pulsatile arterial function and stiffness, 16 an effect which may also be reversible. 17 However, with a mean age of 62 years, our sample was older than many prior FMD-smoking studies. 4, 15 It is well known that endothelial and vascular function deteriorates with age, 18 and it is possible that the adverse effect of smoking on FMD is attenuated in older subjects. For example, a prior MESA analysis has shown that the effect of particulate matter on FMD is attenuated in older subjects. 19 However, despite these considerations, we found no statistical interaction by age in our models.
Although we confirm the results of prior arterial distensibility data, demonstrating that current smoking is associated with increased carotid distensibility, 20 we found no association with pack-years exposure. In addition, we found that current smoking had the reverse association in the aorta, with evidence for reduced distensibility at this site. Although these findings are hypothesis generating, they suggest that either the endothelial dysfunction or the fragmentation of elastin seen in smokers may be regional in nature. Furthermore, recent data suggest that smoking is associated with higher central aortic pressures that could, over time, reduce local aortic distensibility. 21 As pulse pressure differed between smoking groups, we also conducted sensitivity analyses further adjusting for pulse pressure. This did not change the above findings (data not shown).
Smoking and Subclinical Atherosclerosis
Prior reports from the Atherosclerosis Risk in Communities study have established that increased CIMT is common among current smokers. 22 Similar CIMT findings have also been reported from other cohorts. 20, 23, 24 Our study adds to these data by suggesting that there may be relative reductions in CIMT severity as duration of cessation in former smokers increases.
A significant relationship between smoking and CAC has also previously been reported in MESA, 25 as well as other analyses. 26 However, prior data have not explored the association between CAC and cumulative exposure by packyears of smoke exposure. MESA provides an opportunity to test this and, indeed, we found that former smokers in the highest quartile of pack-years have approximately twice the odds of having any CAC, compared with the lowest quartile. However, the negative correlation between cessation interval and pack-years suggests that those former smokers in the lowest quartile of pack-years were also more likely to have the largest cessation interval. In addition, for current smokers, the relative impact of pack-years exposure was not consistent. This finding may relate to several considerations: (1) Cumulative exposure to tobacco may not be an important risk factor for atherosclerosis in persons who are actively smoking as opposed to those who are not, (2) former smokers are older than current smokers with more time elapsed since initial smoking exposure (allowing differences in subclinical atherosclerosis to manifest, in contrast to the more immediate effect of inflammatory markers), and (3) the sample size in the current smoking group may not afford adequate power to detect differences by cumulative exposure.
Importantly, we also found evidence that the association between smoking and CAC may attenuate with time since cessation in former smokers. For example, for every 5 years of abstinence, the independent odds of having any CAC were reduced by ≈6%. These data support the hypothesis that smoking cessation prevents the development of incident CAC. 27 Similar trends were seen for CIMT and for ABI, a marker of more advanced atherosclerosis. However, these results were not as robust as those for the inflammatory markers because we found that the beneficial association between increasing cessation interval and prevalent reductions in atherosclerosis markers was marginally attenuated when our model was further adjusted for pack-years as a potential confounder (Table V in the online-only Data Supplement). Nonetheless, taken together, these results are supportive of the hypothesis that time since cessation in former smokers may be associated with lower relative burdens of subclinical atherosclerosis.
Finally, we extend our understanding of smoking-induced vascular disease by testing for statistical interaction between smoking status, inflammation, and all 3 of our subclinical atherosclerosis outcomes (CIMT, CAC, and ABI). For example, we found that current smokers with hsCRP≥2 mg/L were almost twice as likely to have any CAC as never smokers without evidence of inflammation. Our results add to prior data from the Cardiovascular Health Study demonstrating that hsCRP is strongly related to both smoking exposure and atherosclerosis burden (measured in that study by ABI). 7 However, by demonstrating statistical interaction for all our subclinical atherosclerosis outcomes, we report compelling and robust new evidence that inflammation may biologically modify the systemic effect of smoking on subclinical atherosclerosis.
Limitations
Because of the cross-sectional nature of this analysis, the temporal sequence cannot be determined. Thus, although the causal role of smoking in CVD is widely accepted, our data cannot be presumed to reflect causal effects. In addition, because these mechanistic cross-sectional data are hypothesis generating in nature, they will require replication and we have presented confidence intervals throughout and neither directly reported P values in our models (except for interaction testing) nor performed adjustments for multiple testing. However, for reference purposes, we did identify results that meet a significance level of both P<0.05 and P<0.001 (the latter satisfying Bonferroni correction). We did not exclude persons with hsCRP≥10 mg/L from the main analyses (levels above this may reflect acute inflammation) 28 ; however, sensitivity analyses excluding individuals with hsCRP above this threshold demonstrated only marginal attenuation in our results suggesting that acute inflammation is not driving the associations between smoking and the inflammatory biomarkers (Table IX in the online-only Data Supplement). Given FMD and cardiac MRI were performed in subsets of the entire sample, it is possible that selection bias could influence the results related to these imaging tests. However, per MESA protocol, subjects undergoing such imaging did not differ significantly from those who did not (Table IV in the online-only  Data Supplement) . 29, 30 In addition, cotinine was only available in a subset of 3965 MESA participants (see methods and Table  I in the online-only Data Supplement). However, these persons were chosen at random to eliminate bias. To test the robustness of our findings, we also repeated the entire analysis using selfreported smoking alone as the exposure variable throughout (ie, those with cotinine measurements were not reclassified). The results of this analysis were quantitatively and qualitatively similar to the results presented above (data not shown). Finally, as this study is cross sectional, demonstrating reduced odds for inflammation or CAC with increasing time elapsed since smoking cessation in the past does not mean that the markers are falling over time in formers smokers, rather that former smokers who give up smoking earlier are more likely to have normal values of these markers at assessment in the future.
Conclusions
In this multi-ethnic study, current smoking status and cumulative exposure were more strongly associated with inflammation and subclinical-atherosclerosis than former or never smoking. Although smoking did not seem to influence vascular dynamics and function in this older cohort, subclinical atherosclerosis appeared most severe in those smokers with concomitant elevations in inflammatory markers, with evidence supporting effect modification. These associations attenuated with time since quitting in former smokers. In sum, this study provides insights into mechanisms by which smoking leads to CVD, supporting the link between smoking, inflammation, and atherosclerosis. Our findings also help to explain the cardiovascular benefit of smoking cessation and suggest potential strategies for monitoring both the harm of new tobacco products and the benefits of smoking cessation on vascular health.
